The effects of extended evaluation on depressive symptoms in children and adolescents

Jeanne W. Rintelmann, Graham J. Emslie, A. John Rush, Thomas Varghese, Christina M. Gullion, Robert A. Kowatch, Carroll W. Hughes

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.

Original languageEnglish (US)
Pages (from-to)149-156
Number of pages8
JournalJournal of Affective Disorders
Volume41
Issue number2
DOIs
StatePublished - Nov 25 1996

Fingerprint

Depression
Fluoxetine
Major Depressive Disorder
Outpatients
Randomized Controlled Trials
Placebos
Therapeutics

Keywords

  • Adolescent
  • Child
  • Extended evaluation
  • Major depressive disorder
  • Predicting response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Rintelmann, J. W., Emslie, G. J., Rush, A. J., Varghese, T., Gullion, C. M., Kowatch, R. A., & Hughes, C. W. (1996). The effects of extended evaluation on depressive symptoms in children and adolescents. Journal of Affective Disorders, 41(2), 149-156. https://doi.org/10.1016/S0165-0327(96)00084-5

The effects of extended evaluation on depressive symptoms in children and adolescents. / Rintelmann, Jeanne W.; Emslie, Graham J.; Rush, A. John; Varghese, Thomas; Gullion, Christina M.; Kowatch, Robert A.; Hughes, Carroll W.

In: Journal of Affective Disorders, Vol. 41, No. 2, 25.11.1996, p. 149-156.

Research output: Contribution to journalArticle

Rintelmann, JW, Emslie, GJ, Rush, AJ, Varghese, T, Gullion, CM, Kowatch, RA & Hughes, CW 1996, 'The effects of extended evaluation on depressive symptoms in children and adolescents', Journal of Affective Disorders, vol. 41, no. 2, pp. 149-156. https://doi.org/10.1016/S0165-0327(96)00084-5
Rintelmann, Jeanne W. ; Emslie, Graham J. ; Rush, A. John ; Varghese, Thomas ; Gullion, Christina M. ; Kowatch, Robert A. ; Hughes, Carroll W. / The effects of extended evaluation on depressive symptoms in children and adolescents. In: Journal of Affective Disorders. 1996 ; Vol. 41, No. 2. pp. 149-156.
@article{52ca681efb204c698d6f03f9e1690179,
title = "The effects of extended evaluation on depressive symptoms in children and adolescents",
abstract = "A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.",
keywords = "Adolescent, Child, Extended evaluation, Major depressive disorder, Predicting response",
author = "Rintelmann, {Jeanne W.} and Emslie, {Graham J.} and Rush, {A. John} and Thomas Varghese and Gullion, {Christina M.} and Kowatch, {Robert A.} and Hughes, {Carroll W.}",
year = "1996",
month = "11",
day = "25",
doi = "10.1016/S0165-0327(96)00084-5",
language = "English (US)",
volume = "41",
pages = "149--156",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The effects of extended evaluation on depressive symptoms in children and adolescents

AU - Rintelmann, Jeanne W.

AU - Emslie, Graham J.

AU - Rush, A. John

AU - Varghese, Thomas

AU - Gullion, Christina M.

AU - Kowatch, Robert A.

AU - Hughes, Carroll W.

PY - 1996/11/25

Y1 - 1996/11/25

N2 - A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.

AB - A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.

KW - Adolescent

KW - Child

KW - Extended evaluation

KW - Major depressive disorder

KW - Predicting response

UR - http://www.scopus.com/inward/record.url?scp=0030602263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030602263&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(96)00084-5

DO - 10.1016/S0165-0327(96)00084-5

M3 - Article

C2 - 8961043

AN - SCOPUS:0030602263

VL - 41

SP - 149

EP - 156

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 2

ER -